Loading…
Agios Pharmaceuticals, Inc. is projected to rise to $37.67 by 2027, a +15% move from its current price of $32.75. AGIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $31.74 | $32.75 | $33.80 | 0.00% |
| Aug 2 | $31.32 | $32.75 | $34.24 | 0.00% |
| Aug 3 | $31.01 | $32.75 | $34.59 | 0.00% |
| Aug 4 | $30.75 | $32.75 | $34.88 | 0.00% |
| Aug 5 | $30.52 | $32.75 | $35.14 | +0.01% |
| Aug 6 | $30.32 | $32.75 | $35.38 | +0.01% |
| Aug 7 | $30.13 | $32.75 | $35.60 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.13 | $32.75 | $35.60 | +0.01% |
| Week 2 | $29.11 | $32.76 | $36.85 | +0.02% |
| Week 3 | $28.36 | $32.76 | $37.84 | +0.02% |
| Week 4 | $27.73 | $32.76 | $38.70 | +0.03% |
| Week 5 | $27.19 | $32.76 | $39.47 | +0.04% |
| Week 6 | $26.72 | $32.77 | $40.18 | +0.05% |
| Week 7 | $26.29 | $32.77 | $40.85 | +0.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company that discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
The PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. Agios was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. In addition, it developed tebapivat, AG-181, and AG-236, among other programs for metabolic and hematologic conditions.
AGIO is currently priced at $32.75 per share, with a market capitalization of $1.95B and a rank of 1929. This position places it among smaller-cap healthcare stocks with a focus on cellular metabolism and PK-targeted therapies. The long-range forecast shows a path of rising averages and expanding value from 2026 through 2050.
A major floor 25.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 34.4% above — a clean break opens room to run.
A major ceiling 45.8% above — clearing it would confirm fresh momentum.
Key AGIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AGIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $35.42 | Sell | $35.01 | Sell |
| MA 10 | $36.64 | Sell | $36.22 | Sell |
| MA 20 | $38.56 | Sell | $36.81 | Sell |
| MA 50 | $34.15 | Sell | $35.04 | Sell |
| MA 100 | $31.80 | Buy | $33.17 | Sell |
| MA 200 | $31.68 | Buy | $32.65 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.78 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -162.22 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.98 | Sell |
| ROC (12) | -17.96 | Sell |
| Bollinger %B (20,2) | -0.02 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | -1.46 | Sell |
| Ultimate (7,14,28) | 19.90 | Buy |
| Momentum (10) | -5.97 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 34.48 | Sell |
| ADX (14) | 22.73 | Sell |
| ATR (14) | 1.02 | Info |
The 30-day technical picture is bullish in sentiment. RSI14 sits at 40, with the SMA50 at $34.15 and the SMA200 at $31.68. Immediate support is identified at $32.75 and resistance at $44.01.
The current 30-day range runs from a low of $26.61 to a high of $40.31, with an annualized volatility of 60% suggesting notable price movement potential over the short horizon.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $24.43 | $32.75 | $41.48 | 0% | Neutral | |
| $29.62 | $37.67 | $50.90 | +15% | Neutral | |
| $33.78 | $44.41 | $62.60 | +36% | Bullish | |
| $42.97 | $58.06 | $84.58 | +77% | Bullish | |
| $51.93 | $71.88 | $107.64 | +119% | Bullish | |
| $56.38 | $79.81 | $122.39 | +144% | Bullish | |
| $63.16 | $91.26 | $142.98 | +179% | Bullish | |
| $64.08 | $94.41 | $150.80 | +188% | Bullish | |
| $66.91 | $100.42 | $163.26 | +207% | Bullish | |
| $79.03 | $120.74 | $199.54 | +269% | Bullish | |
| $119.17 | $197.52 | $349.51 | +503% | Bullish | |
| $240.47 | $459.78 | $898.00 | +13.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $24.43 | $32.75 | $38.27 | +0.00% |
| August 2026 | $28.48 | $33.54 | $40.49 | +2.40% |
| September 2026 | $27.58 | $32.78 | $40.19 | -2.24% |
| October 2026 | $27.40 | $32.83 | $40.73 | +0.13% |
| November 2026 | $27.84 | $33.56 | $42.06 | +2.25% |
| December 2026 | $27.06 | $32.82 | $41.48 | -2.23% |
Click any year to see its month-by-month AGIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Agios Pharmaceuticals, Inc.'s 2026 outlook centres on $32.75, within a $24.43 to $41.48 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, AGIO could reach as high as $50.90, with a base case around $37.67 and support toward $29.62 — roughly +15% from $32.75. Price action looks broadly range-bound.
Expect AGIO to range from $33.78 to $62.60 through 2028. The $44.41 average target implies a +36% move from current prices. That is up +18% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The AGIO price prediction for 2029 points to an average of $58.06 (low $42.97, high $84.58) — a potential gain of +77% on today's $32.75. Momentum favours further upside here.
In 2030, AGIO is projected to trade between $51.93 and $107.64, averaging $71.88 — a potential gain of +119% from today's $32.75. That is up +24% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Agios Pharmaceuticals, Inc.'s 2031 outlook centres on $79.81, within a $56.38 to $122.39 range. That is up +11% on the projected 2030 average. That marks a +144% change versus current levels. Momentum favours further upside here.
By 2032, AGIO could reach as high as $142.98, with a base case around $91.26 and support toward $63.16 — roughly +179% from $32.75. Buyers look set to stay in control over this stretch.
Expect AGIO to range from $64.08 to $150.80 through 2033. The $94.41 average target implies a +188% move from current prices. That is up +3% on the projected 2032 average. Momentum favours further upside here.
The AGIO price prediction for 2034 points to an average of $100.42 (low $66.91, high $163.26) — a potential gain of +207% on today's $32.75. Buyers look set to stay in control over this stretch.
In 2035, AGIO is projected to trade between $79.03 and $199.54, averaging $120.74 — a potential gain of +269% from today's $32.75. That is up +20% on the projected 2034 average. Momentum favours further upside here.
Agios Pharmaceuticals, Inc.'s 2040 outlook centres on $197.52, within a $119.17 to $349.51 range. That is up +64% on the projected 2035 average. That marks a +503% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, AGIO could reach as high as $898.00, with a base case around $459.78 and support toward $240.47 — roughly +13.0x from $32.75. Momentum favours further upside here.
Investing $1,000 in AGIO today (≈ 30.534351 AGIO) could be worth
$14,038.98
+$13,038.98 (+1304%) by 2050 · US Dollar
Based on the average projected AGIO price of $459.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AGIOwould be worth at today's price.
$1,000 invested in AGIO on Jul 30, 2025 (≈ 26.638252 AGIO) would be worth
$872.4
-$127.6 (-12.8%) today · 0.87× · US Dollar
Based on a AGIO entry price of $37.54 vs. today's $32.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $36.28 | $902.7 | -9.7% |
| 1 month ago | $37.11 | $882.51 | -11.7% |
| 3 months ago | $28.16 | $1,163 | +16.3% |
| 6 months ago | $27.44 | $1,193.51 | +19.4% |
| 1 year ago | $37.54 | $872.4 | -12.8% |
| All time (5.0y) ago | $48.19 | $679.6 | -32.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AGIO forecast.
Our base-case forecast reaches $66.00 around 2030.
Implied market cap at $66.00: $3.93B
The multi-year forecast outlines a clear upward trajectory in average price from 2026 through 2050. The 2026 average is $32.75 with a 0% ROI, followed by rising averages: 2027 $37.67 (15%), 2028 $44.41 (35.6%), 2029 $58.06 (77.3%), 2030 $71.88 (119.5%). The trajectory continues to 2031 $79.81 (143.7%), 2032 $91.26 (178.7%), 2033 $94.41 (188.3%), 2034 $100.42 (206.6%), 2035 $120.74 (268.7%).
By 2040 the average reaches $197.52 (503.1%), and by 2050 it is $459.78 (1303.9%). The sentiment is BULLISH from 2027 onward, with broader upside implied by the higher midpoints and max values, including a max of $898.00 in 2050. These are estimates and not guarantees; actual results may vary.
Tap a question to reveal the answer.
Avg $71.88, Min $51.93, Max $107.64; ROI 119.5%; Sentiment BULLISH.
Current price $32.75; Market cap $1.95B.
Yes—the 2027 forecast shows a Max of $50.90, with Min $29.62 and Avg $37.67; ROI 15%; Sentiment NEUTRAL.
Avg $197.52, Min $119.17, Max $349.51; ROI 503.1%; Sentiment BULLISH.
Avg $459.78, Min $240.47, Max $898.00; ROI 1303.9%; Sentiment BULLISH.
Agios Pharmaceuticals, Inc. Community Discussion
0Share your Agios Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.